Tusamitamab ravtansine
Based on 1 publication(s) in Google Scholar
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8.
For research use only. We do not sell to patients.
- Purity : 99.50%
- CAS No.: 2254086-60-5
- Molecular Weight:148000 (average)
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P99681
Labetuzumab govitecanAnti-CEACAM5 ADC -
HY-141601
Telisotuzumab vedotinAnti-c-MET ADC -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC -
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-132254A
Sacituzumab govitecan (solution)Trop-2 ADC -
HY-P99813
Patritumab deruxtecanHER3-Directed ADC -
HY-P99016A
Enfortumab vedotin-ejfvNectin-4 ADC -
HY-P3239
Belantamab mafodotinAnti-BCMA ADC -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-P99107A
Brentuximab vedotin (solution)ADC
Publications Citing Use of MedChemExpress (MCE) Tusamitamab ravtansine
More
Biological Activity
Description
In Vitro
The antibody component of SAR408701 binds to the extracellular domain of CEACAM5, initiating the internalization of the ADC into the tumor cell, followed by the subsequent release of DM4 within the cytoplasm. DM4 elicits its cytotoxic effects by disrupting microtubule assembly, inducing cell cycle arrest, and initiating apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2254086-60-5
-
Appearance Liquid
-
Molecular Weight 148000 (average)
-
Color Colorless to light yellow
-
SMILES
[Tusamitamab ravtansine]
-
Synonyms
SAR-408701; HuMAb2-3-SPDB-DM4
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Protocols
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lorenzo Belluomini, et al. Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. Cancers (Basel). 2023 Nov 10;15(22):5368. [Content Brief]
[2]. Ye-Jin Kim, et al. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. Front Oncol. 2023 Feb 27:13:1124039. [Content Brief]
[3]. Gazzah A, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tusamitamab ravtansine Related Classifications
HY-P99542 Related Classifications
Powered by Bioz